RESTORE THERAPEUTICS LLC
Biotech
ReStore Liposome, an antibody-conjugated liposomal nanoparticle that delivers a sphingosine-1-phosphate analog (TySIPonate) and a novel NADPH oxidase inhibitor to restore lung vascular barrier integri
- Grants
- $450K
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS | $224,984 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS | $224,984 |
Federal grant · SBIR/STTRPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2652 | Finch Therapeutics, Inc. | — | $4.5M |
| 2653 | TARTAN LLC | — | $130K |
| 2654 | NEUIMMUNE, INC. | — | $125K |
| 2655 | RESTORE THERAPEUTICS LLC | — | — |
| 2656 | nVector, Inc. | — | $125K |
| 2657 | Sustained Therapeutics Inc. | — | $100K |
| 2658 | GALIBRA NEUROSCIENCE, INC. | — | $100K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe Vision LossPRNewswire
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.